
Another experimental drug meant to slow the damage of Alzheimer’s appears poised to join a growing arsenal of new treatments for this memory-robbing disease. In research published online Monday in the Journal of the American Medical Association and presented simultaneously at the Alzheimer’s Association International Conference in Amsterdam, the drug donanemab slowed memory and thinking declines in early symptomatic Alzheimer’s patients by more than one-third. About 47% of those taking the medication had no decline on a key measure of thinking over a year, compared to 29% of patients on a placebo. “If approved, we believe donanemab can provide clinically meaningful benefits for people with this disease and the possibility of completing their course of treatment as early as 6 months once their amyloid plaque is cleared,” Anne White, executive vice president of Eli Lilly and president of Lilly Neuroscience, said in a company news release. “We must continue to remove any barriers in access to amyloid-targeting therapies and diagnostics in an already complex healthcare ecosystem for Alzheimer’s disease.” The company added that it has already completed an application for traditional approval from the U.S. Food and Drug Administration. “People living with early, symptomatic Alzheimer’s disease are still working, enjoying trips, sharing quality time with family — they want to feel like themselves, for longer,” Dr. Mark Mintun, group vice president of neuroscience research &… read on > read on >